RY 175.42 -0.2162% SHOP 157.15 -0.958% TD 79.04 0.0886% ENB 61.42 0.7711% BN 86.09 -0.3934% TRI 231.36 0.0562% CNQ 47.61 0.8046% CP 105.71 -1.4083% CNR 154.12 -1.2811% BMO 133.23 -0.2396% BNS 77.09 -3.3839% CSU 4762.73 -0.5755% CM 89.48 -0.633% MFC 45.25 -0.2645% ATD 82.67 -0.4336% NGT 58.69 2.2296% TRP 68.72 0.7034% SU 54.51 -1.1067% WCN 268.52 0.1492% L 186.4 1.1998%
Last update at 2024-12-03T16:48:00Z
GE HealthCare says major academic medical center adopts Hospital Pulse Tile
Fri 18 Oct 24, 01:20 PMBest Medical Device Stocks to Buy for 2024
Mon 07 Oct 24, 12:00 AMGE HealthCare Technologies Inc. (GEHC): A Cheap New Stock To Invest In Now
Sun 06 Oct 24, 05:24 PMThe New Face of GE: Why Aerospace Might Be Worth the Wait
Sat 05 Oct 24, 09:10 AMIs GE Healthcare Technologies Inc. (GEHC) the Best Young Stock To Buy Now?
Sun 29 Sep 24, 06:05 AMGE HealthCare announces cash dividend for third quarter of 2024
Wed 18 Sep 24, 08:50 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | 2512.00M | 2875.00M | 2710.00M | 2091.00M |
| Minority interest | -51.00000M | -46.00000M | -51.00000M | -29.00000M |
| Net income | 1916.00M | 2247.00M | 2058.00M | 1524.00M |
| Selling general administrative | 3631.00M | 3563.00M | 3237.00M | 3591.00M |
| Selling and marketing expenses | - | - | - | - |
| Gross profit | 7179.00M | 7174.00M | 6767.00M | 6548.00M |
| Reconciled depreciation | 633.00M | 625.00M | 630.00M | 659.00M |
| Ebit | 2522.00M | 2795.00M | 2720.00M | 2124.00M |
| Ebitda | 3222.00M | 3540.00M | 3406.00M | 2838.00M |
| Depreciation and amortization | 700.00M | 745.00M | 686.00M | 714.00M |
| Non operating income net other | - | - | - | - |
| Operating income | 2522.00M | 2795.00M | 2720.00M | 2124.00M |
| Other operating expenses | 15819.00M | 14790.00M | 14444.00M | 14509.00M |
| Interest expense | 77.00M | 40.00M | 66.00M | 88.00M |
| Tax provision | 563.00M | 600.00M | 652.00M | 410.00M |
| Interest income | - | 34.00M | 49.00M | 36.00M |
| Net interest income | -77.00000M | -6.00000M | -17.00000M | -52.00000M |
| Extraordinary items | - | - | - | - |
| Non recurring | - | - | - | - |
| Other items | - | - | - | - |
| Income tax expense | 563.00M | 600.00M | 652.00M | 410.00M |
| Total revenue | 18341.00M | 17585.00M | 17164.00M | 16633.00M |
| Total operating expenses | 4657.00M | 4379.00M | 4047.00M | 4424.00M |
| Cost of revenue | 11162.00M | 10411.00M | 10397.00M | 10085.00M |
| Total other income expense net | -10.00000M | 80.00M | -10.00000M | -33.00000M |
| Discontinued operations | 18.00M | 18.00M | 11839.00M | -128.00000M |
| Net income from continuing ops | 1949.00M | 2275.00M | 2058.00M | 1681.00M |
| Net income applicable to common shares | 1916.00M | 2247.00M | 13846.00M | 1524.00M |
| Preferred stock and other adjustments | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 32454.00M | 27539.00M | 26308.00M | 24228.00M | - |
| Intangible assets | 1253.00M | 1520.00M | 1847.00M | 1603.00M | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 61.00M | 417.00M | 88.00M | 98.00M | - |
| Total liab | 25144.00M | 18177.00M | 9632.00M | 9477.00M | - |
| Total stockholder equity | 7133.00M | 9357.00M | 16655.00M | 14727.00M | - |
| Deferred long term liab | - | 82.00M | 77.00M | 71.00M | - |
| Other current liab | 3000.00M | 2336.00M | 2247.00M | 2417.00M | - |
| Common stock | 5.00M | 11235.00M | 17692.00M | 15566.00M | - |
| Capital stock | 5.00M | 0.00000M | 17692.00M | 15566.00M | - |
| Retained earnings | 1326.00M | - | - | - | - |
| Other liab | - | 2240.00M | 2324.00M | 2699.00M | - |
| Good will | 12936.00M | 12813.00M | 12892.00M | 11868.00M | - |
| Other assets | 3302.00M | 2534.00M | 1993.00M | 2315.00M | - |
| Cash | 2494.00M | 1445.00M | 554.00M | 994.00M | - |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 8981.00M | 7191.00M | 6761.00M | 6524.00M | - |
| Current deferred revenue | 1918.00M | 1896.00M | 1864.00M | 1813.00M | - |
| Net debt | 7369.00M | 6804.00M | -117.00000M | -526.00000M | - |
| Short term debt | 1116.00M | 15.00M | 110.00M | 132.00M | - |
| Short long term debt | 1006.00M | 15.00M | 6.00M | 4.00M | - |
| Short long term debt total | 9863.00M | 8249.00M | 437.00M | 468.00M | - |
| Other stockholder equity | 6493.00M | 18801.00M | -1037.00000M | -839.00000M | - |
| Property plant equipment | - | 2314.00M | 2235.00M | 2202.00M | - |
| Total current assets | 9410.00M | 8318.00M | 7000.00M | 5896.00M | - |
| Long term investments | 357.00M | 322.00M | 341.00M | 344.00M | - |
| Net tangible assets | - | -4976.00000M | 1916.00M | 1256.00M | - |
| Short term investments | - | - | - | - | - |
| Net receivables | 4254.00M | 4301.00M | 3791.00M | 2657.00M | - |
| Long term debt | 8436.00M | 8234.00M | 31.00M | 31.00M | - |
| Inventory | 1960.00M | 2155.00M | 1946.00M | 1594.00M | - |
| Accounts payable | 2947.00M | 2944.00M | 2540.00M | 2162.00M | - |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -691.00000M | -1878.00000M | -1037.00000M | -839.00000M | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1524.00M | 702.00M | 286.00M | 375.00M | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 23044.00M | 19221.00M | 19308.00M | 18332.00M | - |
| Capital lease obligations | 421.00M | 386.00M | 400.00M | 433.00M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -398.00000M | -1761.00000M | 19986.00M | -325.00000M |
| Change to liabilities | 619.00M | 242.00M | 199.00M | -48.00000M |
| Total cashflows from investing activities | -398.00000M | -1761.00000M | -323.00000M | -325.00000M |
| Net borrowings | 8204.00M | -12.00000M | -16.00000M | -59.00000M |
| Total cash from financing activities | -822.00000M | -263.00000M | -21544.00000M | -1574.00000M |
| Change to operating activities | -81.00000M | 251.00M | 9.00M | 84.00M |
| Net income | 1949.00M | 2275.00M | 2058.00M | 1681.00M |
| Change in cash | 890.00M | -451.00000M | 143.00M | 35.00M |
| Begin period cash flow | 561.00M | 1012.00M | 869.00M | 834.00M |
| End period cash flow | 1451.00M | 561.00M | 1012.00M | 869.00M |
| Total cash from operating activities | 2113.00M | 1607.00M | 1687.00M | 1989.00M |
| Issuance of capital stock | - | - | - | - |
| Depreciation | 633.00M | 625.00M | 630.00M | 659.00M |
| Other cashflows from investing activities | -92.00000M | -47.00000M | -2.00000M | -46.00000M |
| Dividends paid | - | - | - | - |
| Change to inventory | -402.00000M | -435.00000M | 100.00M | -173.00000M |
| Change to account receivables | -231.00000M | -1336.00000M | -221.00000M | -272.00000M |
| Sale purchase of stock | - | - | - | - |
| Other cashflows from financing activities | -819.00000M | -246.00000M | -21524.00000M | -1511.00000M |
| Change to netincome | -341.00000M | 13.00M | -12876.00000M | 215.00M |
| Capital expenditures | 310.00M | 248.00M | 259.00M | 331.00M |
| Change receivables | - | - | - | - |
| Cash flows other operating | - | - | - | - |
| Exchange rate changes | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - |
| Change in working capital | -256.00000M | -1370.00000M | -52.00000M | -387.00000M |
| Stock based compensation | - | - | -931.00000M | 151.00M |
| Other non cash items | -776.00000M | -523.00000M | -670.00000M | -525.00000M |
| Free cash flow | 1803.00M | 1359.00M | 1428.00M | 1658.00M |
Sector: Healthcare Industry: Health Information Services
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GEHC GE HealthCare Technologies Inc. |
-0.575 0.69% | 82.50 | 22.91 | 20.12 | 2.01 | 5.52 | 2.39 | 13.30 |
| VEEV Veeva Systems Inc Class A |
0.38 0.17% | 227.84 | 54.61 | 33.22 | 12.83 | 6.73 | 11.14 | 58.84 |
| MTHRF M3 Inc |
- -% | 10.18 | 29.72 | 25.00 | 0.05 | 4.38 | 0.04 | 0.12 |
| MTHRY M3 Inc |
-0.005 0.10% | 4.95 | 31.84 | 26.25 | 0.05 | 4.60 | 0.04 | 0.12 |
| HQY HealthEquity Inc |
0.70 0.69% | 102.36 | 123.86 | 42.37 | 6.88 | 3.38 | 7.41 | 26.13 |
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
500 West Monroe Street, Chicago, IL, United States, 60661
| Name | Title | Year Born |
|---|---|---|
| Mr. Peter J. Arduini | President, CEO & Director | 1965 |
| Mr. James K. Saccaro | VP & CFO | 1973 |
| Dr. Taha Kass-Hout M.D., M.S. | Chief Science & Technology Officer | 1972 |
| Mr. Frank R. Jimenez Esq. | VP, General Counsel & Corporate Secretary | 1965 |
| Mr. Jan Makela | President & CEO of Imaging | 1969 |
| Mr. George Andrew Newcomb | Controller & Chief Accounting Officer | 1967 |
| Mr. Jahid Khandaker | Chief Information Officer | NA |
| Ms. Carolynne Borders | Chief Investor Relations Officer | NA |
| Ms. Rana Strellis | Chief Corporate Marketing & Communications Officer | NA |
| Mr. Thomas J. Westrick | President & CEO of Patient Care Solutions | 1969 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...